White House Dismisses Janet Woodcock As Permanent FDA Commissioner Candidate: Bloomberg
The Biden Administration has ruled out the nomination of acting FDA commissioner Janet Woodcock as permanent head of…
Controversial Aduhelm To Administered At More Than 300 Hospitals: Nikkei’s
Eisai Co Ltd (OTC:ESALY) and its U.S. partner Biogen Inc’s (NASDAQ:BIIB) Alzheimer’s treatment Aduhelm (aducanumab) will be used by more than 300 American…
Biogen’s New Alzheimer’s Drug Turned Away By Veterans Affairs
The Department of Veterans Affairs (VA) has decided not to include the new Alzheimer’s drug developed by Biogen Inc (NASDAQ:BIIB)…
Biogen’s Alzheimer’s Drug Aduhelm Review Could Have Been Handled Differently, Says FDA Chief: STAT News
Acting FDA Commissioner Janet Woodcock pushed back against media questions about the agency’s controversial approval of Alzheimer’s treatment,…
Bristol Myers Inks Licensing Pact For Eisai’s Folate Receptor ADC Drug, Lays Out Over $3B For Rights
Eisai Co Ltd (OTC:ESALY) and Bristol-Myers Squibb Co (NYSE:BMY) have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization…